Changes in Beneficial Ownership · 4
Replimune Group, Inc.
REPLNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2628945-1_4seq1.xml
Filing details
- Report period
- 2026-11-02
- Issuer
- Replimune Group, Inc.
- Issuer CIK
- 0001737953
- Trading symbol
- REPL
Reporting owner 1
- Name
- Dhingra Kapil
- Reporting owner CIK
- 0001456849
- Relationship
- Director
- Address
- C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN, MA, 01801
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-02 | M · Form 4 | 43,169 | A | 1.75[F1] | 43,169 | D |
| Common Stock | 2026-11-02 | S · Form 4 | 21,500[F2] | D | 19.00[F3] | 21,669 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 1.75 | 2026-11-02 | M · Form 4 | 43,169 | D | 0 | [F4] | 2027-01-21 | Common Stock | 43,169 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The reporting person exercised the non-qualified stock option due to its upcoming expiration date.↩ 1
- F2
- Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the exercise of the Reporting Person's non-qualified stock option into Shares.↩ 1
- F3
- The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $18.99 to $19.03 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.↩ 1
- F4
- All of the Shares underlying this non-qualified stock option vested on January 21, 2017.↩ 1
Signature 1
- Signed
- /s/ Shawn Glidden, attorney-in-fact
- Date
- 2026-11-03
Company context
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.